Inductive Bio

Inductive Bio operates an AI-powered virtual lab platform that accelerates small molecule drug discovery by enabling medicinal chemists to evaluate chemistry ideas at unprecedented scale. The platform pairs scientists with AI chemistry assistants that run millions of in silico experiments to predict how molecules will behave in the body, surfacing the strongest hypotheses for wet-lab testing. Its Beacon-1 class of AI models, built on a pre-competitive ADMET data consortium and fine-tuned to specific chemical spaces, have achieved state-of-the-art accuracy with three consecutive first-place finishes in OpenADMET blind challenges. The Compass software provides a virtual lab bench interface, while the Indy AI assistant automates time-consuming chemistry operations. Inductive also leads a $21M ARPA-H initiative with Amgen to develop AI drug toxicity models. The company serves dozens of biotech partners across therapeutic areas and has helped multiple programs achieve development candidates. Inductive Bio is SOC 2 compliant and headquartered in the United States.